Abstract 249P
Background
Chemoradiotherapy (CCRT) is the primary treatment strategy for locally advanced cervical cancer (LACC) patients. Since June 2016, Brunei patients with LACC have been treated locally. However, no treatment response has been evaluated. As the first attempt in Brunei, this study aims to assess the treatment response of patients with LACC to the completing CCRT performed locally.
Methods
A retrospective cohort study on LACC patients referred to The Brunei Cancer Centre (TBCC) who met the inclusion criteria and had CCRT within the period between June 2016 and December 2019. Data was collected from TBCC patient database. All statistical analyses were carried out using R Studio Version 1.1.463 on Windows 10 where Shapiro-Wilk, Fisher’s exact and Mann-Whitney test was used. Inclusion criteria was confirmed histological diagnosis of squamous or adenocarcinoma or mixed LACC from stages IB to IIIB whom had started or completed CCRT within the period between June 2016 and December 2019. DFS is calculated in months starting from the completion of brachytherapy until the end of the study. OS is calculated in months starting from the time of diagnosis until the end of the study. Research proposal was granted ethics approval by the joint PAPRSB IHS Research and Ethics Committee and Medical and Health Research and Ethics Committee, Ministry of Health of Brunei Darussalam.
Results
40 patients were evaluated for analysis with mean age of 46.80 ± 12.23 years. Majority of the patients had a tumor diameter of ≥5cm (52.5%) and initial stage of 2B (55%). 90% of patients were compliant to chemotherapy. After completion of CCRT, 85% of patients had tumor regression. Upon follow-up, 10 patients had relapse with majority having initial stage of 2B (60%), tumor diameter of ≥5cm (90%) and tumor grade of G3 (70%). A significant difference was observed between the living status of patients, tumor response and tumor diameter in relapse and non-relapse patients with P values of <0.001, 0.002 and 0.009, respectively. 6 patients passed away due to cancer mortality.
Conclusions
There was an overall satisfactory outcome, tolerance and compliance to CCRT. Patients in high-risk group had higher incidence of relapse and had poor prognosis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session